news
TAmiRNA at SURGER-I Innsbruck Congress 2024
We are thrilled to announce that TAmiRNA will participate in the SURGER-I Innsbruck Congress on December 12–13, 2024. This premier event brings together leading experts, researchers, and practitioners to explore advancements in hepatopancreatobiliary surgery and transplantation. As a proud sponsor, we will showcase our hepatomiR® kit, the first CE-IVD microRNA biomarker for the pre-operative assessment of liver function. Attendees can find us featured [...]
Webinar Announcement
🔬 Join us for an insightful webinar on transcriptomics where we will delve into cutting-edge strategies for biomarker discovery, basic research, and translational applications. Whether you're focused on diagnostics or overcoming the challenges of low-input sample analysis, this webinar is designed for you! Title: Harnessing Transcriptomics: microRNA and mRNA analysis for Biomarker Discovery, Basic Research, and Translational Applications What to Expect: Comprehensive Transcriptomics [...]
TAmiRNA at Precision EV Forum in Cambridge
Excited to share that TAmiRNA and Evercyte will join forces at the upcoming Precision EV Forum in Cambridge! 🚀 As key members of the EVscale® consortium, they’ll be showcasing cutting-edge solutions in EV (extracellular vesicles) characterization and therapeutics. TAmiRNA will present its advanced multiomic capabilities for RNA cargo characterization, aiding in biomarker discovery. Evercyte will highlight its clinical-grade EVs produced from telomerized MSCs, [...]
Eager to lern more about differential miRNA expression patterns in Type 2 diabetes mellitusEager to lern more about differential miRNA expression patterns in Type 2 diabetes mellitus
biomarker, bone diseases, bone fracture risk assessment, diabetes, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA
Eager to lern more about differential miRNA expression patterns in Type 2 diabetes mellitus
Excited to share our latest study on the link between Type 2 Diabetes Mellitus (T2DM) and bone fragility using miRNA profiling in a polygenic mouse model! 🧬🦴 🔍 Research Highlights: We utilized an unbiased genome-wide approach to identify dysregulated miRNAs in serum, bone marrow, and bone of the TallyHo/JngJ (TH) mouse model, which closely mirrors T2DM in humans. Key findings include upregulation of [...]
Celebrating the Nobel Prize in Physiology or Medicine 2024!
Congratulations to Victor Ambros and Gary Ruvkun, this year’s Nobel Laureates, for their pioneering discovery of microRNAs—tiny but powerful molecules that regulate gene expression and have reshaped our understanding of biology, aging, cancer, and development. At TAmiRNA, we’ve been deeply inspired by this breakthrough and have dedicated over 10 years to harnessing the potential of microRNAs. We’ve developed cutting-edge diagnostic tools that leverage [...]
TAmiRNA at the GSEV 2024 Scientific Conference
We are thrilled to announce that TAmiRNA will contribute a poster at the upcoming German Society for Extracellular Vesicles (GSEV) Autumn Meeting 2024, presenting our recent advancements in the biodistribution of extracellular vesicles (EVs). The poster will be presented by our expert, Magdalena Mecking. Don’t miss this opportunity to explore TAmiRNA's latest advancements regarding transcriptomic characterization of EVs. Meet Magdalena at the GSEV [...]
Eager to lern more about neuron-derived extracellular vesicles as predictive biomarkers
A new study from the University of Trieste explores the potential of microRNA (miRNA) profiles in neuron-derived extracellular vesicles (NDEVs) as predictive biomarkers for adverse drug reactions (ADRs) in children receiving ketamine. This research, leveraging TAmiRNA's Next-Generation Sequencing (NGS)-based miND® pipeline, identified specific miRNAs (miR-18a-3p, miR-484, and miR-548az-5p) as potential tools to predict ketamine-induced ADRs. This breakthrough not only advances our understanding of [...]
TAmiRNA at ASEV/CzeSEV meeting
TAmiRNA, Evercyte and Phoenestra, three leading biotech companies, will present their cutting-edge work in for production and characterization of clinical-grade extracellular vesicles (EVs) at the upcoming shared Annual Meeting of the Austrian and Czechia Societies for Extracellular Vesicles (ASEV & CzeSEV) on 16th/17th September in Vienna. As esteemed ASEV members, TAmiRNA and Evercyte are well-known participants at these meetings and this year will take [...]
TAmiRNA at EUROTOX 2024 in Copenhagen
On September 10, our CEO & CSO, Dr. Matthias Hackl, will discuss “Small RNA-sequencing based discovery of microRNAs for CNS-injury biomarkers” during the EUROTOX Short Orals Session. He’ll highlight the efforts of TAmiRNA and the IMI consortium TransBioLine in advancing microRNAs as biomarkers of drug-induced brain injury. TAmiRNA will also bring a poster (P06-01) to the conference, authored by Senior Scientist, Dr. Kseniya Khamina-Kotisch, [...]
TAmiRNA at SSCC/SGK in Zürich
TAmiRNA will spotlight its miND® NextGen small RNA-sequencing platform and the hepatomiR® test—Europe's first CE-IVD marked test for liver function microRNA biomarkers—at the Zürich conference. These innovations highlight TAmiRNA's strengths in microRNA diagnostic development. Dr. Matthias Hackl, CEO and Chief Scientific Officer, will present "MicroRNAs as a Novel Class of Biomarkers" on Friday, September 6, in Session 6: New Technologies. He will discuss [...]